Related Experiment Video
Updated: Mar 18, 2026
In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains
Yan Q Xiong1, Wessam Abdelhady2, Chieh 'Genna' Tang2
1Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA David Geffen School of Medicine at UCLA, Los Angeles, CA, USA yxiong@ucla.edu.
Background:
MRSA strains of clonal complexes (CCs) 5, 8, 30 and 45 are leading causes of complicated endovascular infections associated with suboptimal clinical outcomes. Telavancin is a novel anti-MRSA agent that both inhibits bacterial cell wall synthesis and disrupts membranes by depolarization.
Methods:
In this study, we compared the in vitro susceptibility and in vivo efficacy of telavancin versus daptomycin in an experimental rabbit infective endocarditis (IE) model caused by four MRSA strains representing each of the above CC types.
Results:
All study strains were susceptible to telavancin (MICs of ≤0.12 mg/L) and daptomycin (MICs of ≤0.5 mg/L). In vitro time-kill analyses revealed that supra-MIC levels of telavancin were effective at preventing regrowth at 24 h of incubation. In the IE animal model for all CC types, treatment with telavancin produced significantly greater reductions in MRSA counts as compared with daptomycin-treated animals in all target tissues. Moreover, telavancin-treated animals had a significantly higher percentage of sterile tissue cultures versus daptomycin-treated animals (e.g. 78%-100% versus 0% sterile vegetations and 100% versus 0%-11% sterile kidneys and spleen, in the telavancin- and daptomycin-treated animals, respectively).
Conclusions:
These results suggest that telavancin exhibits significantly greater efficacies versus daptomycin in treating experimental IE caused by MRSA clinical isolates across four common CC types.
Insights
Telavancin demonstrated superior efficacy compared to daptomycin in treating experimental methicillin-resistant Staphylococcus aureus (MRSA) endocarditis in rabbits. This novel agent achieved better bacterial clearance and higher sterile tissue rates across multiple MRSA clonal complexes.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) clonal complexes (CCs) 5, 8, 30, and 45 are primary causes of severe endovascular infections with poor outcomes.
- Telavancin is a new antibiotic targeting MRSA by inhibiting cell wall synthesis and disrupting bacterial membranes.
Purpose of the Study:
- To compare the in vitro susceptibility and in vivo efficacy of telavancin against daptomycin.
- To evaluate efficacy in an experimental rabbit infective endocarditis (IE) model using MRSA strains from common CC types.
Main Methods:
- MRSA strains from CCs 5, 8, 30, and 45 were used.
- In vitro susceptibility testing and time-kill assays were performed.
- An experimental rabbit IE model was employed to compare telavancin and daptomycin efficacy.
Main Results:
- All tested MRSA strains were susceptible to both telavancin and daptomycin.
- Telavancin prevented bacterial regrowth at 24 hours in vitro.
- Telavancin significantly reduced MRSA bacterial counts and increased sterile tissue cultures compared to daptomycin in the rabbit IE model.
Conclusions:
- Telavancin showed significantly greater efficacy than daptomycin in treating experimental IE caused by MRSA.
- These findings support telavancin as a potent therapeutic option for MRSA endovascular infections.
More Related Videos
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:28Antimicrobial Effectiveness
01:25Mechanism of Antibiotic Resistance in MRSA
01:18Endocarditis III: Medical Management
01:25Endocarditis I: Introduction